Elicio Therapeutics, Inc. (NASDAQ:ELTX) Stock Has Consensus Price Target of $15.00

Shares of Elicio Therapeutics, Inc. (NASDAQ:ELTX) have earned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $15.00.

Several research analysts recently issued reports on ELTX shares. Wall Street Zen raised shares of Elicio Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. HC Wainwright reaffirmed a “buy” rating on shares of Elicio Therapeutics in a report on Tuesday, August 18th. B. Riley Financial lowered their price objective on Elicio Therapeutics to $8.00 and set a “buy” rating on the stock in a report on Thursday, September 24th. LADENBURG THALM/SH SH initiated coverage on Elicio Therapeutics in a research report on Thursday, June 18th. They set a “buy” rating and a $12.00 target price on the stock. Finally, Rodman & Renshaw restated a “buy” rating on shares of Elicio Therapeutics in a research note on Monday, June 15th.

Elicio Therapeutics Stock Performance

Shares of NASDAQ ELTX traded down $0.06 during mid-day trading on Tuesday, hitting $1.82. 46,178 shares of the company were exchanged, compared to its average volume of 670,870. The firm has a market cap of $47.80 million, a price-to-earnings ratio of -0.84 and a beta of 1.32. The company has a quick ratio of 2.77, a current ratio of 2.77 and a debt-to-equity ratio of 1.20. Elicio Therapeutics has a 1-year low of $1.71 and a 1-year high of $16.00. The stock has a 50 day simple moving average of $2.43 and a 200-day simple moving average of $6.18.

Elicio Therapeutics (NASDAQ:ELTX) last released its earnings results on Thursday, August 13th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.11. On average, sell-side analysts forecast that Elicio Therapeutics will post -1.90 EPS for the current fiscal year.

Institutional Investors Weigh In On Elicio Therapeutics

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in shares of Elicio Therapeutics in the 2nd quarter valued at about $2,995,000. Shah Capital Management purchased a new stake in shares of Elicio Therapeutics during the 3rd quarter worth approximately $2,275,000. Bank of New York Mellon Corp acquired a new stake in shares of Elicio Therapeutics in the 2nd quarter worth approximately $62,000. Deutsche Bank AG purchased a new position in Elicio Therapeutics in the 2nd quarter valued at approximately $49,000. Finally, Bank of America Corp DE raised its holdings in Elicio Therapeutics by 1,225.2% during the first quarter. Bank of America Corp DE now owns 15,333 shares of the company’s stock worth $164,000 after purchasing an additional 14,176 shares during the last quarter. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Elicio Therapeutics Company Profile

Elicio Therapeutics, Inc is a clinical-stage biotechnology company developing immunotherapies designed to treat cancer by directing immune responses to the lymph nodes, where key immune cells are activated. The company’s technology is based on its Amphiphile platform, which is intended to improve the delivery and activity of therapeutic vaccines and other immune-modulating agents.

Elicio’s lead program is ELI-002, an investigational therapeutic cancer vaccine designed to target common KRAS mutations.